Literature DB >> 28974545

The HRD Decision-Which PARP Inhibitor to Use for Whom and When.

Elise C Kohn1, Jung-Min Lee2, S Percy Ivy2.   

Abstract

Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. Clin Cancer Res; 23(23); 7155-7. ©2017 AACRSee related article by Balasubramaniam et al., p. 7165. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28974545      PMCID： PMC5712252          DOI： 10.1158/1078-0432.CCR-17-2186

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  Ovarian cancer.

Authors:  Gordon C Jayson; Elise C Kohn; Henry C Kitchener; Jonathan A Ledermann
Journal:  Lancet       Date:  2014-04-21       Impact factor: 79.321

2.  FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.

Authors:  Sanjeeve Balasubramaniam; Julia A Beaver; Sara Horton; Laura L Fernandes; Shenghui Tang; Hisani N Horne; Jinzhong Liu; Chao Liu; Sarah J Schrieber; Jingyu Yu; Pengfei Song; William Pierce; Kim J Robertson; Todd R Palmby; Haw-Jyh Chiu; Eunice Y Lee; Reena Philip; Robert Schuck; Rosane Charlab; Anamitro Banerjee; Xiao Hong Chen; Xing Wang; Kirsten B Goldberg; Rajeshwari Sridhara; Geoffrey Kim; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

3.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Eric Pujade-Lauraine; Jonathan A Ledermann; Frédéric Selle; Val Gebski; Richard T Penson; Amit M Oza; Jacob Korach; Tomasz Huzarski; Andrés Poveda; Sandro Pignata; Michael Friedlander; Nicoletta Colombo; Philipp Harter; Keiichi Fujiwara; Isabelle Ray-Coquard; Susana Banerjee; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Patricia Pautier
Journal:  Lancet Oncol       Date:  2017-07-25       Impact factor: 41.316

4.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Authors:  Elizabeth M Swisher; Kevin K Lin; Amit M Oza; Clare L Scott; Heidi Giordano; James Sun; Gottfried E Konecny; Robert L Coleman; Anna V Tinker; David M O'Malley; Rebecca S Kristeleit; Ling Ma; Katherine M Bell-McGuinn; James D Brenton; Janiel M Cragun; Ana Oaknin; Isabelle Ray-Coquard; Maria I Harrell; Elaina Mann; Scott H Kaufmann; Anne Floquet; Alexandra Leary; Thomas C Harding; Sandra Goble; Lara Maloney; Jeff Isaacson; Andrew R Allen; Lindsey Rolfe; Roman Yelensky; Mitch Raponi; Iain A McNeish
Journal:  Lancet Oncol       Date:  2016-11-29       Impact factor: 41.316

Review 5.  The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality.

Authors:  S Percy Ivy; Johann de Bono; Elise C Kohn
Journal:  Trends Cancer       Date:  2016-11-23

Review 6.  PARP inhibitors: Synthetic lethality in the clinic.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

Review 7.  Targeting the DNA Damage Response in Cancer.

Authors:  Mark J O'Connor
Journal:  Mol Cell       Date:  2015-11-19       Impact factor: 17.970

8.  Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Authors:  Joyce F Liu; William T Barry; Michael Birrer; Jung-Min Lee; Ronald J Buckanovich; Gini F Fleming; Bj Rimel; Mary K Buss; Sreenivasa Nattam; Jean Hurteau; Weixiu Luo; Philippa Quy; Christin Whalen; Lisa Obermayer; Hang Lee; Eric P Winer; Elise C Kohn; S Percy Ivy; Ursula A Matulonis
Journal:  Lancet Oncol       Date:  2014-09-10       Impact factor: 41.316

9.  Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Authors:  Joo Ern Ang; Charlie Gourley; C Bethan Powell; Hilda High; Ronnie Shapira-Frommer; Vincent Castonguay; Jacques De Greve; Tina Atkinson; Timothy A Yap; Shahneen Sandhu; Susana Banerjee; Lee-May Chen; Michael L Friedlander; Bella Kaufman; Amit M Oza; Ursula Matulonis; Louise J Barber; Iwanka Kozarewa; Kerry Fenwick; Ioannis Assiotis; James Campbell; Lina Chen; Johann S de Bono; Martin E Gore; Christopher J Lord; Alan Ashworth; Stan B Kaye
Journal:  Clin Cancer Res       Date:  2013-08-06       Impact factor: 12.531

10.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 13.312
  10 in total
  8 in total

Review 1.  Synthetic Lethality in Ovarian Cancer.

Authors:  Akshaya Chandrasekaran; Kevin M Elias
Journal:  Mol Cancer Ther       Date:  2021-09-13       Impact factor: 6.261

2.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Authors:  Robert L Coleman; Gini F Fleming; Mark F Brady; Elizabeth M Swisher; Karina D Steffensen; Michael Friedlander; Aikou Okamoto; Kathleen N Moore; Noa Efrat Ben-Baruch; Theresa L Werner; Noelle G Cloven; Ana Oaknin; Paul A DiSilvestro; Mark A Morgan; Joo-Hyun Nam; Charles A Leath; Shibani Nicum; Andrea R Hagemann; Ramey D Littell; David Cella; Sally Baron-Hay; Jesus Garcia-Donas; Mika Mizuno; Katherine Bell-McGuinn; Danielle M Sullivan; Bruce A Bach; Sudipta Bhattacharya; Christine K Ratajczak; Peter J Ansell; Minh H Dinh; Carol Aghajanian; Michael A Bookman
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

Review 3.  Update on PARP Inhibitors in Breast Cancer.

Authors:  Alexandra S Zimmer; Mitchell Gillard; Stanley Lipkowitz; Jung-Min Lee
Journal:  Curr Treat Options Oncol       Date:  2018-04-11

Review 4.  Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.

Authors:  Yolanda Jerez; Ivan Márquez-Rodas; Inmaculada Aparicio; Manuel Alva; Miguel Martín; Sara López-Tarruella
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

5.  Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.

Authors:  Rüveyda Dok; Marieke Bamps; Mary Glorieux; Peihua Zhao; Anna Sablina; Sandra Nuyts
Journal:  Int J Cancer       Date:  2019-07-27       Impact factor: 7.396

Review 6.  Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.

Authors:  Daniel R Principe
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639

7.  Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.

Authors:  Razan Sheta; Magdalena Bachvarova; Marie Plante; Marie-Claude Renaud; Alexandra Sebastianelli; Jean Gregoire; Jamilet Miranda Navarro; Ricardo Bringas Perez; Jean-Yves Masson; Dimcho Bachvarov
Journal:  J Transl Med       Date:  2020-11-19       Impact factor: 5.531

8.  Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.

Authors:  Daniel R Principe; Matthew Narbutis; Regina Koch; Ajay Rana
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.